PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31176754-0	2019	Evaluating the optimal time for amikacin administration with respect to haemodialysis using an in vitro pharmacodynamic simulation against epidemic nosocomial OXA-48 producing Klebsiella pneumoniae ST405 strains.	Amikacin	32-40	OXA-48	Klebsiella pneumoniae	159-165	
33842497-5	2021	In vitro, fosfomycin plus amikacin showed synergistic and bactericidal effect against strains producing VIM-1, VIM-1 plus DHA-1, and OXA-48 plus CTX-M-15.	Amikacin	26-34	OXA-48	Klebsiella pneumoniae	133-139	
33842497-7	2021	In vivo, fosfomycin and amikacin and its combination reduced the spleen bacterial concentration compared with controls groups in animals infected by K. pneumoniae producing VIM-1 and OXA-48 plus CTX-M-15.	Amikacin	24-32	OXA-48	Klebsiella pneumoniae	183-189	
33842497-12	2021	Fosfomycin plus amikacin or plus gentamycin may be useful to treat infections by OXA-48 plus CTX-M-15 or KPC-3 producer strains, respectively.	Amikacin	16-24	OXA-48	Klebsiella pneumoniae	81-87